2011 - Transplantomics and Biomarkers in Transplantation


Immune Monitoring +/- Imaging?

5.4 - Detection and Clinical Relevance of Donor Specific HLA Antibodies

Presenter: Frans H.J., Claas, Leiden, The Netherlands
Authors: Frans H.J. Claas


Detection and Clinical Relevance of Donor Specific HLA Antibodies

Frans H.J. Claas, Leiden University Medical Center, Leiden, The Netherlands

For several decades complement dependent cytotoxicity (CDC) has been the standard assay for HLA antibody screening and the final crossmatch before transplantation. Life was easy as a positive crossmatch, due to donor specific HLA antibodies (DSA), was considered a contra-indication for transplantation.

In the meantime new and more sensitive assays have been introduced, mainly based on the reactivity of antibodies with isolated HLA molecules attached to a solid phase. The advantage of these techniques is the higher degree of reproducibility compared to CDC and the fact that also non-complement fixing antibodies can be detected.

Currently, these assays are widely used for the determination of HLA antibodies before transplantation and the definition of acceptable and unacceptable HLA mismatches facilitating virtual crossmatching. The outcome of these assays plays also a determinative factor in the decision to apply desensitization protocols for particular donor-recipient combinations. Furthermore, patients are monitored after transplantation for the presence of DSA as more and more data suggest that the formation of DSA after transplantation is associated with a higher risk of graft loss due to chronic rejection.

Since the introduction of these assays, the frequency of HLA antibody screening in (potential) transplant recipients has increased enormously. In contrast to the old situation, the clinical relevance of HLA antibodies , detectable in solid phase assays only, is not well established. The presence of DSA before transplantation is certainly not a contra-indication for transplantation but rather a risk factor. This risk may vary between no risk at all to a high risk to develop an acute humoral rejection. The same holds true for the development of DSA after transplantation. On the population level patients with DSA have a poorer prognosis than patients without DSA but quiet some patients with DSA have an excellent graft function for many years.

The challenge is to develop strategies by which these techniques can be used to determine the relevance of DSA in a specific donor-recipient combination.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi